prostate cancerSubscribe to prostate cancer

International radiopharmaceutical company Clarity has licensed technology developed at the University of Melbourne for imaging and treating prostate cancer.

Researchers have identified some common genetic cancer mutations could indicate the presence of much more influential rare “hidden” mutations that could lead to earlier detection of prostate cancer.